ERRATUMERRATUM for "Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis".

MLA

Leder, Benjamin Z., et al. “ERRATUMERRATUM for ‘Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.’” Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 8, Aug. 2020, p. 1. EBSCOhost, https://doi.org/10.1210/clinem/dgaa301.

APA

Leder, B. Z., Mitlak, B., Hu, M.-Y., Hattersley, G., & Bockman, R. S. (2020). ERRATUMERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.” Journal of Clinical Endocrinology & Metabolism, 105(8), 1. https://doi.org/10.1210/clinem/dgaa301

Chicago

Leder, Benjamin Z, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, and Richard S Bockman. 2020. “ERRATUMERRATUM for ‘Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.’” Journal of Clinical Endocrinology & Metabolism 105 (8): 1. doi:10.1210/clinem/dgaa301.